Enhancing Clinical Outcomes in Hepatocellular Carcinoma

This Webcast contains video and downloadable slides from Enhancing Clinical Outcomes in Hepatocellular Carcinoma: A Multidisciplinary Expert Practice^SMMeeting, a prIME Oncology educational activity that was held on 3 November 2011 in San Francisco, California.

FACULTY

Co-Chairs
Ghassan Abou-Alfa, MD
Memorial Sloan-Kettering Cancer Center
New York, New York, United States

Alan P. Venook, MD
University of California, San Francisco
San Francisco, California, United States

Faculty
Massimo Colombo, MD
University of Milan
Milan, Italy

Richard S. Finn, MD
David Geffen School of Medicine
University of California, Los Angeles
Los Angeles, California, United States

Yujin Hoshida, MD, PhD
Broad Institute
Massachusetts Institute of Technology and Harvard University
Cambridge, Massachusetts, United States

Jorge A. Marrero, MD, MS
University of Michigan
Ann Arbor, Michigan, United States

Target Audience
This educational activity is specifically designed for medical oncologists, hepatologists, surgical oncologists, radiation oncologists, and other healthcare providers interested and/or involved in the treatment of patients with hepatocellular carcinoma.

		Expert Discussion
		Downloadable Slides

TOPICS

Why is the incidence of HCC rising?
Jorge A. Marrero, MD

Multidisciplinary management of HCC: An evolving story
Massimo Colombo, MD

Molecular classification of HCC: Importance of translational research
Yujin Hoshida, MD, PhD

Targeting signaling pathways in HCC: Novel molecular targeted therapies on the horizon
Richard S. Finn, MD

Case #1: Advanced unresectable HCC: A multidisciplinary clinicopathologic conference
Ghassan Abou-Alfa, MD, and faculty panel

Case #2: Treatment options for a patient with pretreated HCC: A multidisciplinary clinicopathologic conference
Alan P. Venook, MD, and faculty panel

LEARNING OBJECTIVES

Upon completion of this educational activity, participants should be able to:

Discuss the epidemiology and risk factors for hepatocellular carcinoma (HCC), and discuss strategies for screening and surveillance
Examine the current understanding of HCC tumor biology with regard to gene profiling, molecular targets, biomarkers, and risk-assessment strategies
Describe current standards of care and recent advances in the treatment of advanced unresectable HCC, including the role of targeted therapies, patient selection, and appropriate response-monitoring strategies
Discuss the efficacy and safety of treatment options for patients with metastatic HCC beyond first-line therapy, including chemotherapy and novel targeted agents
Identify the importance of a multidisciplinary approach in the treatment of patients with HCC

Organizer
This meeting is a prIME Oncology activity.

Support
Support for this educational activity has been provided by Bristol-Myers Squibb, Abbott, Bayer Healthcare, and Onyx Pharmaceuticals.

FACULTY

Target Audience

TOPICS

LEARNING OBJECTIVES

Organizer

Support